Literature DB >> 11380911

Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy.

K Hashino1, M Ishii, M Iemura, T Akagi, H Kato.   

Abstract

BACKGROUND: We compared the efficacy and safety of additional intravenous immune globulin (IVIG) therapy with steroid pulse therapy in patients with IVIG-resistant Kawasaki disease.
METHODS: Two-hundred and sixty-two consecutive patients had been treated with a single dose of IVIG (2 g/kg) and aspirin (30 mg/kg per day). Thirty-five patients (13.4%) were not clinical responders to the initial IVIG treatment. They received an additional IVIG treatment (1 g/kg) within 48 h after the initial treatment. Seventeen patients (6.5%) did not respond to the additional IVIG treatment. We randomly divided these patients into two groups: group 1 consisted of eight patients who were treated with a single additional dose of IVIG (1 g/kg), while group 2 consisted of nine patients who were treated with steroid pulse therapy.
RESULTS: The IVIG-resistant patients had a high incidence of coronary artery lesions (CAL; 48.6%). Five patients (62.5%) in group 1 had CAL, including two patients who each had a giant aneurysm and three patients who each had a small aneurysm. Seven patients (77.8%) in group 2 had CAL, including two patients who each had a giant aneurysm, two patients who each had a small coronary aneurysm and three patients who each showed transient dilatation during steroid pulse therapy. There was no significant difference in the incidence of CAL between the two groups. The duration of high fever in group 2 (1.4~0.7 days) was significantly shorter than in group 1 (4.8~3.4 days; P<0.05). The medical costs for the treatment of patients in group 2 (113, 012 yen +/- 22,084) were significantly lower than those for group 1 (144,194 yen +/- 12,914; P<0.05).
CONCLUSIONS: Steroid pulse therapy may be useful in the treatment of patients with IVIG-resistant Kawasaki disease who experience prolonged fever. However, transient dilatation of the coronary artery is observed during steroid pulse therapy, so careful echocardiographic examination should be performed for those patients receiving steroid pulse therapy for the sake of early detection of coronary artery abnormalities.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11380911     DOI: 10.1046/j.1442-200x.2001.01373.x

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  50 in total

1.  Kawasaki disease with exceptional cutaneous manifestations.

Authors:  Thierry Passeron; Valérie Olivier; Nicolas Sirvent; Ali Khalfi; Patrick Boutté; Jean-Philippe Lacour
Journal:  Eur J Pediatr       Date:  2002-04       Impact factor: 3.183

Review 2.  Update on the treatment of Kawasaki disease in childhood.

Authors:  Robert P Sundel
Journal:  Curr Rheumatol Rep       Date:  2002-12       Impact factor: 4.592

3.  Coronary risk factors in Kawasaki disease treated with additional gammaglobulin.

Authors:  M Miura; H Ohki; T Tsuchihashi; H Yamagishi; Y Katada; K Yamada; Y Yamashita; A Sugaya; O Komiyama; H Shiro
Journal:  Arch Dis Child       Date:  2004-08       Impact factor: 3.791

Review 4.  Use of corticosteroids during acute phase of Kawasaki disease.

Authors:  Jeong Jin Yu
Journal:  World J Clin Pediatr       Date:  2015-11-08

5.  A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease.

Authors:  Koichi Sakata; Kenji Hamaoka; Sei-Ichiro Ozawa; Ayumi Niboshi; Takao Yoshihara; Tesuo Nishiki; Yumi Nakagawa; Kikuko Kazuta; Yoshiko Morimoto; Yasutaka Kamiya; Toru Yamamoto; Yoshihiro Horii; Sachiko Kido
Journal:  Eur J Pediatr       Date:  2007-06       Impact factor: 3.183

6.  Kawasaki disease with DIC as a complication.

Authors:  V K Parvathy; A Davis Manuel; S Criton; G Rajesh
Journal:  Indian J Pediatr       Date:  2007-11       Impact factor: 1.967

7.  Intravenous pulsed corticosteroid therapy for primary treatment of Kawasaki disease.

Authors:  Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.592

8.  Recurrent Kawasaki disease.

Authors:  S Balasubramanian; R Ganesh
Journal:  Indian J Pediatr       Date:  2009-05-27       Impact factor: 1.967

9.  Infliximab treatment for pediatric refractory Kawasaki disease.

Authors:  Laura L Blaisdell; Jennifer A Hayman; Adrian M Moran
Journal:  Pediatr Cardiol       Date:  2011-07-20       Impact factor: 1.655

10.  Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease.

Authors:  Taek Jin Lee; Ki Hwan Kim; Jin-Kyong Chun; Dong Soo Kim
Journal:  Yonsei Med J       Date:  2008-10-31       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.